Condition: Pneumococcal Infectious Disease · Sponsor: Sinovac Life Sciences Co., Ltd.
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.
This description comes directly from the study's public registry record.
Ye-qing Tong · +86 13971078410 · 63382251@qq.com
Always discuss trial participation with your own doctor first.
| Qichun District Center for Disease Prevention and Control | Huanggang, Hubei, China | Recruiting |
| Xiangzhou District Center for Disease Prevention and Control | Xiangyang, Hubei, China | Recruiting |
| Xian'an District Center for Disease Prevention and Control | Xianning, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07300644